• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

底物结合环突变对恶性疟原虫烯酰基辅酶 A 还原酶的结构、动力学和抑制作用的影响。

Effect of substrate binding loop mutations on the structure, kinetics, and inhibition of enoyl acyl carrier protein reductase from Plasmodium falciparum.

机构信息

Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India.

出版信息

IUBMB Life. 2011 Jan;63(1):30-41. doi: 10.1002/iub.412. Epub 2011 Jan 13.

DOI:10.1002/iub.412
PMID:21280175
Abstract

Enoyl acyl carrier protein reductase (ENR), which catalyzes the final and rate limiting step of fatty acid elongation, has been validated as a potential drug target. Triclosan is known to be an effective inhibitor for this enzyme. We mutated the substrate binding site residue Ala372 of the ENR of Plasmodium falciparum (PfENR) to Methionine and Valine which increased the affinity of the enzyme towards triclosan to almost double, close to that of Escherichia coli ENR (EcENR) which has a Methionine at the structurally similar position of Ala372 of PfENR. Kinetic studies of the mutants of PfENR and the crystal structure analysis of the A372M mutant revealed that a more hydrophobic environment enhances the affinity of the enzyme for the inhibitor. A triclosan derivative showed a threefold increase in the affinity towards the mutants compared to the wild type, due to additional interactions with the A372M mutant as revealed by the crystal structure. The enzyme has a conserved salt bridge which stabilizes the substrate binding loop and appears to be important for the active conformation of the enzyme. We generated a second set of mutants to check this hypothesis. These mutants showed loss of function, except in one case, where the crystal structure showed that the substrate binding loop is stabilized by a water bridge network.

摘要

烯酰基辅酶 A 还原酶(ENR)催化脂肪酸延长的最后一个限速步骤,已被验证为一个有潜力的药物靶点。三氯生是已知的这种酶的有效抑制剂。我们突变了恶性疟原虫(PfENR)ENR 的底物结合位点残基 Ala372 为蛋氨酸和缬氨酸,这使得酶对三氯生的亲和力增加了近一倍,接近于结构上与 PfENR 的 Ala372 相似的位置为蛋氨酸的大肠杆菌 ENR(EcENR)。PfENR 的突变体的动力学研究和 A372M 突变体的晶体结构分析表明,更疏水的环境增强了酶对抑制剂的亲和力。由于与 A372M 突变体的额外相互作用,如晶体结构所揭示的那样,三氯生衍生物对突变体的亲和力增加了三倍,而对野生型的亲和力则增加了三倍。该酶具有一个保守的盐桥,稳定了底物结合环,似乎对酶的活性构象很重要。我们生成了第二组突变体来验证这一假设。这些突变体显示出功能丧失,除了一种情况,在这种情况下,晶体结构表明底物结合环由一个水桥网络稳定。

相似文献

1
Effect of substrate binding loop mutations on the structure, kinetics, and inhibition of enoyl acyl carrier protein reductase from Plasmodium falciparum.底物结合环突变对恶性疟原虫烯酰基辅酶 A 还原酶的结构、动力学和抑制作用的影响。
IUBMB Life. 2011 Jan;63(1):30-41. doi: 10.1002/iub.412. Epub 2011 Jan 13.
2
X-ray crystallographic analysis of the complexes of enoyl acyl carrier protein reductase of Plasmodium falciparum with triclosan variants to elucidate the importance of different functional groups in enzyme inhibition.X 射线晶体学分析恶性疟原虫烯酰基辅酶 A 还原酶与三氯生变体的复合物,以阐明不同功能基团在酶抑制中的重要性。
IUBMB Life. 2010 Jun;62(6):467-76. doi: 10.1002/iub.327.
3
3D-QSAR studies on triclosan derivatives as Plasmodium falciparum enoyl acyl carrier reductase inhibitors.三氯生衍生物作为恶性疟原虫烯酰基辅酶 A 还原酶抑制剂的 3D-QSAR 研究。
SAR QSAR Environ Res. 2010 Jul;21(5-6):527-45. doi: 10.1080/1062936X.2010.502297.
4
Epigallocatechin gallate is a slow-tight binding inhibitor of enoyl-ACP reductase from Plasmodium falciparum.表没食子儿茶素没食子酸酯是恶性疟原虫烯酰-ACP还原酶的一种缓慢紧密结合型抑制剂。
Biochem Biophys Res Commun. 2008 Dec 26;377(4):1238-42. doi: 10.1016/j.bbrc.2008.10.135. Epub 2008 Nov 4.
5
Mutational analysis of the triclosan-binding region of enoyl-ACP (acyl-carrier protein) reductase from Plasmodium falciparum.恶性疟原虫烯脂酰-ACP(酰基载体蛋白)还原酶三氯生结合区域的突变分析。
Biochem J. 2004 Aug 1;381(Pt 3):735-41. doi: 10.1042/BJ20040302.
6
Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase.三氯生抗疟类似物组合文库的设计及其对恶性疟原虫烯酰-酰基载体蛋白还原酶抑制作用的计算机模拟筛选
Eur J Med Chem. 2009 Jul;44(7):3009-19. doi: 10.1016/j.ejmech.2008.12.028. Epub 2009 Jan 19.
7
Design, development, synthesis, and docking analysis of 2'-substituted triclosan analogs as inhibitors for Plasmodium falciparum enoyl-ACP reductase.设计、开发、合成 2'-取代三氯生类似物并进行对接分析,作为疟原虫烯酰基-ACP 还原酶抑制剂。
IUBMB Life. 2009 Nov;61(11):1083-91. doi: 10.1002/iub.258.
8
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives.疟疾烯酰酰基载体蛋白还原酶的二芳基醚抑制剂的合成、生物活性及X射线晶体结构分析。第1部分:4'-取代的三氯生衍生物。
Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52. doi: 10.1016/j.bmcl.2005.08.044. Epub 2005 Sep 29.
9
Structural basis for triclosan and NAD binding to enoyl-ACP reductase of Plasmodium falciparum.三氯生和烟酰胺腺嘌呤二核苷酸与恶性疟原虫烯酰-ACP还原酶结合的结构基础。
Biochem Biophys Res Commun. 2001 Apr 27;283(1):224-8. doi: 10.1006/bbrc.2001.4747.
10
Structural basis for the variation in triclosan affinity to enoyl reductases.三氯生对烯酰还原酶亲和力变化的结构基础。
J Mol Biol. 2004 Oct 8;343(1):147-55. doi: 10.1016/j.jmb.2004.08.033.

引用本文的文献

1
Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.合理化对嗜麦芽窄食单胞菌FabI1烯酰-ACP还原酶抑制作用的结合动力学
Biochemistry. 2017 Apr 4;56(13):1865-1878. doi: 10.1021/acs.biochem.6b01048. Epub 2017 Mar 21.
2
Celastrol inhibits Plasmodium falciparum enoyl-acyl carrier protein reductase.雷公藤红素抑制恶性疟原虫烯脂酰-酰基载体蛋白还原酶。
Bioorg Med Chem. 2014 Nov 1;22(21):6053-6061. doi: 10.1016/j.bmc.2014.09.002. Epub 2014 Sep 15.
3
Dynamics of Plasmodium falciparum enoyl-ACP reductase and implications on drug discovery.
恶性疟原虫烯酰基 ACP 还原酶的动力学及其对药物发现的影响。
Protein Sci. 2012 Nov;21(11):1734-45. doi: 10.1002/pro.2155. Epub 2012 Oct 9.
4
Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality.金黄色葡萄球菌 FabI:抑制、底物识别及对体内必需性的潜在影响。
Structure. 2012 May 9;20(5):802-13. doi: 10.1016/j.str.2012.03.013.